HAS Group, Biodelphis Therapeutics Partner to Advance Antibody Protease Inhibitor Conjugates

HAS Healthcare Advanced Synthesis and Biodelphis Therapeutics have signed a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease-driving proteases.

This collaboration combines HAS Group’s expertise in complex bioconjugation, process development, and clinical-grade manufacturing with Biodelphis Therapeutics’ APIC platform, a novel drug modality engineered to deliver highly selective protease inhibition directly to diseased tissues.

Under the agreement, the two companies will work closely to accelerate the transition of first-in-class APIC candidates from early development into robust, scalable manufacturing processes. The partnership aims to strengthen the path toward clinical evaluation by integrating Biodelphis’ therapeutic design with HAS/Cerbios’ capabilities in high-quality bioconjugate production.

The partnership marks a shared commitment to advancing next-generation targeted therapies for patients with high unmet medical needs.